Market Research Reports and Industry Reports

New Technologies Initiative: Gateway to Treating Genetic Diseases - Sarepta Therapeutics - Skipping Makes Sense - Restoring Muscle Function in Duchenne Muscular Dystrophy

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Approval of KYNAMRO (ISIS/Sanofi, HoFH), a first systemic Oligonucleotide Antisense (ASO) based therapy has raised expectations from the compounds in pipeline of other companies with similar technology platforms. Highly differentiated, 2nd Generation DNA/RNA-based drugs that work at the fundamental level of gene and protein expression have the potential to bring a paradigm change in treating diseases esp. rare genetic disorders like Familial Hypercholesterolemia (FH), Duchenne Muscular Dystrophy (DMD), TTR (Transthyretin amyloidosis), SMN (spinal muscular atrophy) etc. Noteworthy, amongst them besides ISIS Pharma (ISIS) are Sarepta Therapeutics (SRPT), Prosensa (Pvt.), Regulus (RGLS), Alnylam (ALNY), Idera (IDRA), Santaris (Pvt.), Acuity pharma (merged with Froptix corp.), Arrowhead Research Corporation (ARWR), etc. SRPTs lead compound Eteplirsen (formerly AVI-4658, PhII, based on proprietary exon-skipping technology, exon 51) targets specific mutations in DMD, repairs the mRNA and restores production of functional dystrophin protein = improved muscle functions. Duchenne Muscular Dystrophy (DMD) is a genetic (X-linked recessive) degenerative disease and Becker muscular dystrophy (BMD) is a milder form of DMD where the onset of the disease and disability is delayed.

In this report, we highlight the potential of the SRPTs Phosphorodiamidate Morpholino Oligomer (PMO) and Exon-Skipping technology platform. Key Points described in the report, are:
N/A

List Of Tables

N/A

List Of Figures

N/A

The Service assurance for NFV/SDN: new requirements will lead to vendor opportunity and disruption

CSPs are demanding assurance solutions for NFV/SDN with cloud, analytics and automation features; this change is creating opportunities for vendors and disruption across the assurance value chain.    This strategy

USD 4999View Report

2017 New Zealand Automated Microbiology Market: Molecular Diagnostics, Identification, Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics-- Specimen, Test, and Sales Forecasts, Competitive Strategies, Opportunities

This new report examines current and emerging assays; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over

USD 4850View Report

2017 New Zealand Molecular Diagnostics Market: Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing--Test Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation, Opportunities

This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the molecular diagnostics market during the next five years.Highlights- Five-year test

USD 4250View Report

2016 Molecular Blood Typing, Grouping and Infectious Disease NAT Screening Assays, and Companies Developing New Technologies and Products

This unique market intelligence report from VPGMarketResearch provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product and country for

USD 3850View Report

US Hematology and Flow Cytometry Instruments and Reagents: Supplier Sales and Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts, New Technologies, Instrumentation Review, Emerging Opportunities

VPGMarketResearch.com new study is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the U.S. hematology and flow cytometry markets during the next

USD 9850View Report

UK Hematology and Flow Cytometry Instruments and Reagents: Supplier Sales and Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts, New Technologies, Instrumentation Review, Emerging Opportunities

VPGMarketResearch.coms new study is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the U.K. hematology and flow cytometry markets during the next

USD 6200View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 500
  • Site Licence    $ 1000
  • Enterprisewide Licence    $ 1500
$ 500

Reports Details

Published Date : Mar 2013
No. of Pages :18
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment